Article Versions Notes

de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, van Brakel M, Debets R, Aerts JGJV, van Schaik RHN, et al. Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers. 2021; 13(6):1370. https://doi.org/10.3390/cancers13061370

de With, Mirjam, Daan P. Hurkmans, Esther Oomen-de Hoop, Ayoub Lalouti, Sander Bins, Samira El Bouazzaoui, Mandy van Brakel, Reno Debets, Joachim G. J. V. Aerts, Ron H. N. van Schaik, and et al. 2021. "Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy" Cancers 13, no. 6: 1370. https://doi.org/10.3390/cancers13061370

de With, M., Hurkmans, D. P., Oomen-de Hoop, E., Lalouti, A., Bins, S., El Bouazzaoui, S., van Brakel, M., Debets, R., Aerts, J. G. J. V., van Schaik, R. H. N., Mathijssen, R. H. J., & van der Veldt, A. A. M. (2021). Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers, 13(6), 1370. https://doi.org/10.3390/cancers13061370